- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06942702
Wirksamkeit des Genikularblocks bei der gesamten Knieendoprothetikoperation
Einschätzung der postoperativen analgetischen Wirksamkeit der präoperativ angewandten Genikularblockade bei der Gesamt -Knie -Arthroplastik: Eine randomisierte kontrollierte Studie
This prospective, randomized, double-blind, placebo-controlled trial evaluated the analgesic efficacy of preoperative ultrasound-guided genicular nerve block (GNB) in patients undergoing total knee arthroplasty.
A total of 64 patients were randomly assigned to two groups (32 patients per group). The GNB group received 5 mL of 0.25% bupivacaine at each of three genicular nerve targets, whereas the placebo group received 5 mL of 0.9% normal saline at the same anatomical targets.
All patients underwent standardized general anesthesia and received postoperative multimodal analgesia, including intravenous patient-controlled morphine analgesia.
The primary outcome was movement-evoked pain intensity, assessed using the visual analog scale (VAS) at 24 hours postoperatively. Secondary outcomes included pain scores at other postoperative time points, opioid consumption, and knee range of motion.
Participants and outcome assessors were blinded to group allocation.
Studienübersicht
Status
Detaillierte Beschreibung
Patients scheduled for elective primary unilateral total knee arthroplasty were randomly allocated in a 1:1 ratio to the genicular nerve block (GNB) group or the placebo control group.
Approximately 30 minutes before surgery, all patients underwent an ultrasound-guided injection procedure targeting the superomedial, superolateral, and inferomedial genicular nerves.
Patients in the GNB group received 5 mL of 0.25% bupivacaine at each target (total volume: 15 mL). Patients in the placebo control group received 5 mL of 0.9% normal saline at each corresponding target (total volume: 15 mL).
The injections were performed by an anesthesiologist who was aware of group allocation and was not involved in postoperative outcome assessment. Participants and outcome assessors remained blinded to treatment allocation.
All patients received standardized general anesthesia and postoperative multimodal analgesia, including intravenous paracetamol, intramuscular diclofenac, and patient-controlled intravenous morphine analgesia.
Postoperative pain intensity was assessed using the visual analog scale (VAS) at rest and during movement. The primary outcome was movement-evoked VAS at 24 hours after surgery. Secondary outcomes included other postoperative VAS measurements, morphine consumption, and knee range of motion.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Mersin
-
Mersin, Mersin, Türkei (türkiye), 33120
- Mersin University Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Scheduled for unilateral and primary total knee arthroplasty
- Older than 18 years of age
Exclusion Criteria:
- Younger than 18 years
- Bilateral knee arthroplasty
- Revision case of knee arthroplasty
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Genicular block group
Patients received preoperative ultrasound-guided genicular nerve block with 5 mL of 0.25% bupivacaine injected at each of three anatomical targets: superomedial, superolateral, and inferomedial genicular nerves (total volume: 15 mL). All patients received standardized general anesthesia and postoperative multimodal analgesia, including intravenous patient-controlled morphine analgesia, paracetamol, and diclofenac. |
Patients received preoperative ultrasound-guided genicular nerve block with 5 mL of 0.25% bupivacaine injected at each of three anatomical targets: superomedial, superolateral, and inferomedial genicular nerves (total volume: 15 mL). Standardized postoperative multimodal analgesia consisting of intravenous paracetamol 1 g every 8 hours and intramuscular diclofenac sodium 75 mg every 12 hours during the first 48 postoperative hours, administered to both study groups. Postoperative intravenous patient-controlled analgesia with morphine, programmed to deliver a 1 mg demand dose with a 15-minute lockout interval. The same PCA regimen was used in both study groups. |
|
Placebo-Komparator: placebo
Patients received preoperative ultrasound-guided placebo injections consisting of 5 mL of 0.9% normal saline at each of the same three genicular nerve targets (total volume: 15 mL). All patients received standardized general anesthesia and postoperative multimodal analgesia, including intravenous patient-controlled morphine analgesia, paracetamol, and diclofenac. |
Standardized postoperative multimodal analgesia consisting of intravenous paracetamol 1 g every 8 hours and intramuscular diclofenac sodium 75 mg every 12 hours during the first 48 postoperative hours, administered to both study groups. Postoperative intravenous patient-controlled analgesia with morphine, programmed to deliver a 1 mg demand dose with a 15-minute lockout interval. The same PCA regimen was used in both study groups. Patients received preoperative ultrasound-guided placebo injections consisting of 5 mL of 0.9% normal saline at each of the same three genicular nerve targets (total volume: 15 mL). |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Visual Analog Scale Measure
Zeitfenster: 0-48 hours
|
VAS scores are assessed at 0th, 24th and 48th hours post operatively VAS score consists of 0-10 in numbers, the bigger the number the worse the pain |
0-48 hours
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
opioid consumption
Zeitfenster: 0-48 hours
|
Morphine consumption is assesed by PCA |
0-48 hours
|
|
Range of Motion Measurements
Zeitfenster: 0-48 hours
|
Knee range of motion (ROM) are assessed in degrees during active knee flexion. Measurements are obtained preoperatively and at predefined postoperative time points. Higher values indicate greater knee flexion. |
0-48 hours
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Mustafa Azizoglu, Associated Professor, Mersin university Faculty of Medicine, Department of Anesthesiology and Reanimation
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Schmerzen
- Neurologische Manifestationen
- Postoperative Komplikationen
- Pathologische Prozesse
- Pathologische Zustände, Anzeichen und Symptome
- Anzeichen und Symptome
- Schmerzen, postoperativ
- Organische Chemikalien
- Heterocyclische Verbindungen
- Heterocyclische Verbindungen, Fusionsring
- Untersuchungstechniken
- Klinische Labortechniken
- Diagnosetechniken und Verfahren
- Diagnose
- Alkaloide
- Polycyclische aromatische Kohlenwasserstoffe
- Polycyclische Verbindungen
- Anilides
- Amides
- Anilinverbindungen
- Amine
- Acetanilide
- Anorganische Chemikalien
- Chlorverbindungen
- Heterocyclische Verbindungen, 4 oder mehr Ringe
- Morphinans
- Opiatalkaloide
- Heterocyclische Verbindungen, Brückenring
- Phenanthrenes
- Immunologische Techniken
- Morphinderivate
- Natriumverbindungen
- Immunologische Tests
- Chloride
- Salzsäure
- Hauttests
- Phänomene des Immunsystems
- Antigen-Antikörper-Reaktionen
- Acetaminophen
- Morphium
- Natriumchlorid
- Passive Hautanaphylaxie
Andere Studien-ID-Nummern
- MersinUgenicular
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .